Beta Bionics, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – BBNX
LOS ANGELES–(BUSINESS WIRE)–The DJS Law Group reminds investors of a class action lawsuit against Beta Bionics, Inc. (“Beta Bionics” or “the Company”) (NASDAQ: BBNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of BBNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: July 30, 2025 to February 24, 2026
DEADLINE: November 3, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Beta Bionics touted the safety, efficacy, and commercial success of the iLet Bionic Pancreas insulin pump (“iLet”), the Company’s sole commercialized product. After disclosing that the FDA had issued a Form 483 following an inspection of the Company’s manufacturing facility, Defendants repeatedly assured investors that the agency’s observations concerned only the Company’s criteria for deciding which customer complaints were reportable, that they reflected no underlying problem with the device, and that the complaints the Company would now be required to report were minor events of the kind requiring no medical intervention. In truth, the FDA’s findings reached the Company’s quality management system, its investigation and correction of known device malfunctions, and the risk analysis for the device itself, and the events the Company had failed to report included serious injuries. Defendants continued to reassure investors and to characterize the agency’s concerns as procedural even as further information emerged showing that the unreported events were far more serious than Defendants had represented and that the FDA’s objections were not confined to a difference in regulatory interpretation. Based on these facts, Beta Bionics’ public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260906427280/en/
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]
KEYWORDS: California United States North America
INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal
MEDIA: